N/A
N=73
Real-world Evidence Study on Cystistat
Interstitial Cystitis and Bladder Pain Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT05544695 ↗Enrolled (actual)
73
Serious AEs
1.4%
Results posted
Jan 2026
Primary outcome: Primary: Patient Global Assessment (PGA) — 90.1 percentage of participants (%)
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- intravesical sodium hyaluronate (Cystistat®) (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- MEDA Pharma GmbH & Co. KG
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Global Assessment (PGA) |
90.1 | — |
| SECONDARY Assessment of Bladder Pain/ Interstitial Cystitis Symptom Score |
-13.8; -15.3 | — |
| SECONDARY Assessment of Visual Analogue Scale (VAS) for Bladder Pain |
-42.0; -49.2 | — |
| SECONDARY Assessment of Visual Analogue Scale (VAS) for Urinary Urgency. |
-39.3; -49.2 | — |
| SECONDARY Assessment of Visual Analogue Scale (VAS) for Quality of Life (QoL) |
17.1; 27.2 | — |
Summary
This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime. Cystistat is supplied as a 50 mL solution containing 40 mg of sodium hyaluronate. It is indicated for the temporary replacement of the GAG layer in the bladder.
Eligibility Criteria
Inclusion Criteria
- First prescription of Cystistat according to instructions for use.
- Female patients of any ethnic origin with clinical diagnosis of interstitial cystitis (IC)/bladder pain syndrome (BPS). If in accordance with routine clinical practice at the site, ESSIC diagnostic criteria will be used.
- Age: 18 years and older.
- At least 6 months duration of bladder pain/discomfort symptom(s), e.g. constant bladder pain/discomfort or bladder pain/discomfort when voiding or as a burning sensation between voids as the bladder fills with urine.
- At least one accompanying intermittent or persistent lower urinary tract symptom, such as urinary frequency, urgency, or nocturia during the previous 6 months.
- Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC-SS) > 18 prior to first treatment.
- Written informed consent.
Exclusion Criteria
- Known hypersensitivity reactions to sodium hyaluronate.
- Pregnancy / planned pregnancy or breastfeeding during the course of this NIS.
- Known history of any GAG substitution therapy within the last 2 years.
- Known history of fulguration or resection of Hunner's lesions.
- Known diagnosis of recurrent urinary tract infection or overactive bladder.
- Any other conditions or diseases that can cause similar symptoms, using information from medical history, physical examination findings, laboratory studies (e.g., urine bacterial culture), and other previously performed procedures (e.g., urodynamics, cystoscopy, laparoscopy, radiological studies).
- Patients are not able to fulfil study requirements according to physician's opinion.
Data sourced from ClinicalTrials.gov (NCT05544695). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.